Collaboration brings DFU and Inflammatory Disease Therapy to Greater China Region

Aurealis Therapeutics, (Basel, Switzerland) and AI-based microbiome drug development company Xbiome have entered into an agreement for the clinical development and commercialisation of Aurealis’ investigational Diabetic Foot Ulcer (DFU) and other chronic wounds and inflammatory disease therapy in the Greater China territory. Click to read more...

Related Keywords

China ,Taiwan ,Hong Kong ,Switzerland ,Macao ,Macau General ,Macau ,Chinese ,Donald Xu ,Roger Meier ,Juha Yrj , ,Aurealis Therapeutics ,Diabetic Foot Ulcer ,Greater China ,Mainland China ,Lynx Financial ,Aurealis Chairman ,Bryan Tan ,Managing Partner ,Development ,Aurealis ,Ased ,Hronic ,Therapy ,Biome ,Companies ,Company ,Drug ,